Article: Treatment DURATION-2: efﬁcacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide C. Wysham, R. Bergenstal*, J. Malloy†, P. Yan†, B. Walsh†, J. Malone‡ and K. Taylor† Rockwood Clinic, Spokane, WA, *International Diabetes Center at Park Nicollet, Minneapolis, MN, †Amylin Pharmaceuticals Inc., San Diego, CA and ‡E li Lilly and Company, Indianapolis, IN, USA Accepted 21 December 2010 Abstract Aims In the initial 26-week, double-blind, double-dummy assessment period of the DURATION-2 trial in patients with Type 2 diabetes on metformin, the once-weekly glucagon-lik e peptide 1 (GLP-1) receptor agonist exenatide once-weekly resulted in greater HbA 1cimprovement and weight reduction compared with m aximum approved daily doses of sitagliptin or pioglitazone. This subsequent, 26-week, open-label, uncontro lled assessment period evaluated the safety and efﬁcacy of (i)